SHANGHAI FUDAN H YC-,10
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China. It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clini… Read more
Market Cap & Net Worth: SHANGHAI FUDAN H YC-,10 (FDY)
SHANGHAI FUDAN H YC-,10 (F:FDY) has a market capitalization of $115.17 Million (€112.20 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #16738 globally and #1735 in its home market, demonstrating a 3.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI FUDAN H YC-,10's stock price €0.33 by its total outstanding shares 340000000 (340.00 Million).
SHANGHAI FUDAN H YC-,10 Market Cap History: 2020 to 2026
SHANGHAI FUDAN H YC-,10's market capitalization history from 2020 to 2026. Data shows growth from $38.46 Million to $115.17 Million (22.40% CAGR).
SHANGHAI FUDAN H YC-,10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI FUDAN H YC-,10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of FDY by Market Capitalization
Companies near SHANGHAI FUDAN H YC-,10 in the global market cap rankings as of March 19, 2026.
Key companies related to SHANGHAI FUDAN H YC-,10 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
SHANGHAI FUDAN H YC-,10 Historical Marketcap From 2020 to 2026
Between 2020 and today, SHANGHAI FUDAN H YC-,10's market cap moved from $38.46 Million to $ 115.17 Million, with a yearly change of 22.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €115.17 Million | +6.45% |
| 2025 | €108.19 Million | +4.73% |
| 2024 | €103.30 Million | +86.28% |
| 2023 | €55.46 Million | -8.31% |
| 2022 | €60.48 Million | +24.41% |
| 2021 | €48.62 Million | +26.41% |
| 2020 | €38.46 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SHANGHAI FUDAN H YC-,10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $115.17 Million USD |
| MoneyControl | $115.17 Million USD |
| MarketWatch | $115.17 Million USD |
| marketcap.company | $115.17 Million USD |
| Reuters | $115.17 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.